Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports
Iwona Pietrzak
1
,
Agnieszka Szadkowska
1
Department of Pediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, Poland
Pietrzak I, Szadkowska A. Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports. Pediatric Endocrinology Diabetes and Metabolism. 2021;27(4):305-310. doi:10.5114/pedm.2022.112621.
APA
Pietrzak, I., & Szadkowska, A. (2021). Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports. Pediatric Endocrinology Diabetes and Metabolism, 27(4), 305-310. https://doi.org/10.5114/pedm.2022.112621
Chicago
Pietrzak, Iwona, and Agnieszka Szadkowska. 2021. "Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports". Pediatric Endocrinology Diabetes and Metabolism 27 (4): 305-310. doi:10.5114/pedm.2022.112621.
Harvard
Pietrzak, I., and Szadkowska, A. (2021). Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports. Pediatric Endocrinology Diabetes and Metabolism, 27(4), pp.305-310. https://doi.org/10.5114/pedm.2022.112621
MLA
Pietrzak, Iwona et al. "Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports." Pediatric Endocrinology Diabetes and Metabolism, vol. 27, no. 4, 2021, pp. 305-310. doi:10.5114/pedm.2022.112621.
Vancouver
Pietrzak I, Szadkowska A. Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports. Pediatric Endocrinology Diabetes and Metabolism. 2021;27(4):305-310. doi:10.5114/pedm.2022.112621.
The aim of modern insulin therapy used in the treatment of type 1 diabetes mellitus is to mimic the physiological secretion of insulin in order to ensure stable normoglycemia while maintaining the greatest possible comfort of life for diabetic patients. New ultra-fast insulin analogs that can be administered immediately before a meal contribute to the improvement of postprandial glycemia and the quality of life of patients. We presented two cases illustrating the effectiveness and safety of the use of an ultra-fast-acting insulin analog in the treatment of postprandial hyperglycemia in children with type 1 diabetes.
Keywords
type 1 diabetes mellitus, postprandial hyperglycemia, time in range, ultrafast-acting analog of insulin, children
